|
| related topics |
| {product, market, service} |
| {product, candidate, development} |
| {system, service, information} |
| {condition, economic, financial} |
| {stock, price, share} |
| {property, intellectual, protect} |
| {acquisition, growth, future} |
| {regulation, government, change} |
| {interest, director, officer} |
| {stock, price, operating} |
| {customer, product, revenue} |
|
|
Our independent registered public accounting firm have expressed doubt about our ability to continue as a going concern .
Disruptions in the financial and credit markets may adversely impact the availability and cost of credit and the spending of our customers as well as our ability to raise additional capital, which could adversely affect our business, results of operations and financial condition.
We may need to raise additional funds and take further cost-cutting initiatives to meet our working capital requirements and there can be no assurance that we will be able to obtain new business and/or maintain existing trials in the current economic climate.
We may lose revenue if we experience delays in clinical trials or if we lose contracts.
We may lose future revenue if our major customers decrease their research and development expenditures, or if we lose any of our major customers.
Our quarterly results fluctuate significantly.
Our business strategies are unproven and we are in an early stage of development.
If we fail to continue to meet all applicable Nasdaq Capital Market requirements, our common shares could be delisted. If delisting occurs, it would adversely affect the market liquidity of our common shares.
If we do not continue to enhance our software, we may not be able to meet the evolving needs of our customers.
Changes in government regulations relating to the health care industry could have a material adverse effect on the demand for our services.
We may not be able to capture or establish the market presence necessary to compete in the EDC market.
We may be subject to liability for potential breaches of contracts or a loss of or unauthorized release of clinical trial data.
Our competitive position and business may be adversely affected if we are unable to protect our intellectual property rights or if we infringe upon the intellectual property rights of others.
Full 10-K form ▸
|
|
| related documents |
| 886530--3/17/2008--DATATRAK_INTERNATIONAL_INC |
| 886530--3/13/2006--DATATRAK_INTERNATIONAL_INC |
| 886530--3/16/2007--DATATRAK_INTERNATIONAL_INC |
| 752294--3/26/2010--ELECTRONIC_SYSTEMS_TECHNOLOGY_INC |
| 874734--3/12/2008--OSTEOTECH_INC |
| 724004--6/29/2009--MESA_LABORATORIES_INC_/CO |
| 724004--6/30/2008--MESA_LABORATORIES_INC_/CO |
| 23259--3/31/2006--CT_COMMUNICATIONS_INC_/NC |
| 724004--6/29/2010--MESA_LABORATORIES_INC_/CO |
| 64978--3/13/2006--MERCK_&_CO_INC |
| 911149--4/2/2007--MICRO_COMPONENT_TECHNOLOGY_INC |
| 911149--3/31/2006--MICRO_COMPONENT_TECHNOLOGY_INC |
| 855683--3/17/2009--MILESTONE_SCIENTIFIC_INC/NJ |
| 1279695--3/28/2008--UNIVERSAL_BIOSENSORS_INC |
| 1436083--7/20/2009--New_Millennium_Products |
| 65759--2/17/2010--MICROPAC_INDUSTRIES_INC |
| 28626--9/13/2007--LIFECORE_BIOMEDICAL_INC |
| 911149--3/28/2008--MICRO_COMPONENT_TECHNOLOGY_INC |
| 1043894--4/15/2009--ENVIRO_VORAXIAL_TECHNOLOGY_INC |
| 1042173--3/8/2007--SCIENTIFIC_LEARNING_CORP |
| 1440819--10/21/2010--PAPERWORKS_INC. |
| 1101026--4/14/2010--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 1116463--3/10/2009--ORASURE_TECHNOLOGIES_INC |
| 1114200--3/1/2010--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC |
| 780127--1/7/2009--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 1026650--3/7/2008--ERESEARCHTECHNOLOGY_INC_/DE/ |
| 832101--3/1/2010--IDEX_CORP_/DE/ |
| 799426--4/15/2009--NEW_WORLD_BRANDS_INC |
| 64978--2/28/2007--MERCK_&_CO_INC |
| 866787--10/25/2010--AUTOZONE_INC |
|